BEIJING, May 7 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA),
a leading provider of vaccines in China, today announced that Mr. Weidong
Yin, CEO, and Ms. Helen Yang, International Business Manager, are scheduled
to present at the Brean Murray, Carret & Co. All-Cap All-China Conference
on Monday, May 19, 2008 at 10:15 a.m. Eastern Standard Time at the Waldorf
Astoria in New York, NY.
Ms. Nan Wang, Vice President, and Ms. Vanessa Wu, Senior Financial
Manager, are scheduled to present at the Roth China Discovery Tour 2008 the
same day at 5:20 p.m. Beijing Time at the Regent Hotel in Beijing, China.
Web cast of the Company's presentation at the Brean Murray, Carret &
Co. All-Cap All-China Conference will be available by going to the investor
relations section of Sinovac's Web site at http://www.sinovac.com . A
replay of the presentation will be available for 30 days.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac's
commercialized vaccines include Healive(R) (hepatitis A), Bilive(R)
(combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM)(H5N1).
Sinovac is currently developing Universal Pandemic Influenza vaccine and
Japanese encephalitis vaccine. Additional information about Sinovac is
available on its website, http://www.sinovac.com . To be added to our
distribution list, please email: info@sinovac.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements
are made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar
statements. Among other things, the business outlook and quotations from
management in this press release contain forward-looking statements.
Statements that are not historical facts, including statements about
Sinovac's beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and uncertainties. A
number of important factors could cause actual results to differ materially
from those contained in any forward-looking statement. Sinovac does not
undertake any obligation to update any forward-looking statement, except as
required under applicable law.
For more information, please contact:
Company:
Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x871
Fax: +86-10-6296-6910
Email: info@sinovac.com
Investors:
Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7017
Email: scarrington@theruthgroup.com
Media
Janine McCargo
The Ruth Group
Tel: +1-646-536-7033
Email: jmccargo@theruthgroup.com
SOURCE Sinovac Biotech Ltd.
 back to top
Related links:
http://www.sinovac.com
CONTACT:
Company, Helen G. Yang of Sinovac Biotech
Ltd., +86-10-8289-0088 x871, or fax, +86-10-6296-6910, or email,
info@sinovac.com; Investors, Stephanie Carrington of The Ruth
Group, 646-536-7017, or email, scarrington@theruthgroup.com;
Media, Janine McCargo of The Ruth Group, 646- 536-7033, or
jmccargo@theruthgroup.com, all for Sinovac Biotech Ltd.
|
